- International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 In Process GET IT
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
Times cited: 4
Current strategies for treatment of relapsed/refractory multiple myeloma.
Expert review of hematology.
Times cited: 33
- A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
Leukemia & lymphoma.
Times cited: 7
- Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Information Resource GET IT
- Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT